Covid-19 man­u­fac­tur­ing roundup: Ger­many locks in vac­cine sup­ply un­til 2029; White House an­nounces vac­cine do­na­tion mile­stone

Ger­many’s cab­i­net has ap­proved a plan to spend $3.14 bil­lion to en­sure BioN­Tech, Cure­Vac/GSK, Cor­den­Phar­ma and oth­er vac­cine man­u­fac­tures have the pro­duc­tion ca­pac­i­ty to sup­ply the coun­try with enough Covid-19 vac­cines for fu­ture out­breaks through 2029.

The con­tracts will keep up the in­creased pro­duc­tion ca­pa­bil­i­ties, Reuters re­port­ed Wednes­day. An an­nu­al stand­by fee will help en­sure that enough vac­cine can be pro­duced quick­ly, if need­ed. They al­so give the gov­ern­ment the right to ac­cess pro­duc­tion ca­pac­i­ties if a new pan­dem­ic breaks out.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.